Evidence map›Paper›PMID 29784926›Full record

ReviewNature reviews. Clinical oncology2018

Clinical utility of circulating non-coding RNAs - an update.

Simone Anfossi, Anna Babayan, Klaus Pantel, George A Calin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 283 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
283citing papers in PubMed, 2 pooled it
18.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

283 citing papers in PubMed, 2 syntheses or guidelines pooled it, 439 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Advances in liquid biopsy for bone and soft-tissue sarcomas.International journal of clinical oncology · 2025
    Review
  19. Article
  20. Review

223 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Simone AnfossiDepartment of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Anna BabayanDepartment of Tumour Biology, Centre for Experimental Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Klaus PantelDepartment of Tumour Biology, Centre for Experimental Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. pantel@uke.de.
George A CalinDepartment of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. gcalin@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity Medical Center Hamburg-Eppendorf · DE

Funding

NIH HHS 1 R01 CA182905-01NIH HHS UH3TR00943-01
6 · The paper itself

Abstract

Over the past decade, the amount of research and the number of publications on associations between circulating small and long non-coding RNAs (ncRNAs) and cancer have grown exponentially. Particular focus has been placed on the development of diagnostic and prognostic biomarkers to enable efficient patient management - from early detection of cancer to monitoring for disease recurrence or progression after treatment. Owing to their high abundance and stability, circulating ncRNAs have potential utility as non-invasive, blood-based biomarkers that can provide information on tumour biology and the effects of treatments, such as targeted therapies and immunotherapies. Increasing evidence highlights the roles of ncRNAs in cell-to-cell communication, with a number of ncRNAs having the capacity to regulate gene expression outside of the cell of origin through extracellular vesicle-mediated transfer to recipient cells, with implications for cancer progression and therapy resistance. Moreover, 'foreign' microRNAs (miRNAs) encoded by non-human genomes (so-called xeno-miRNAs), such as viral miRNAs, have been shown to be present in human body fluids and can be used as biomarkers. Herein, we review the latest developments in the use of circulating ncRNAs as diagnostic and prognostic biomarkers and discuss their roles in cell-to-cell communication in the context of cancer. We provide a compendium of miRNAs and long ncRNAs that have been reported in the literature to be present in human body fluids and that have the potential to be used as diagnostic and prognostic cancer biomarkers.

Indexed as

Biomarkers, TumorCell CommunicationCell-Free Nucleic AcidsDisease ProgressionGenome, HumanHumansMicroRNAsNeoplasmsPrognosisRNA, UntranslatedBiomarkers, TumorCell-Free Nucleic AcidsMicroRNAsRNA, Untranslated

Identifiers

PMID29784926
OpenAlexW2803222773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.